KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
26.66
+0.01 (0.04%)
May 4, 2026, 4:00 PM EDT - Market closed
KalVista Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts that cover KalVista Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $30.8, which forecasts a 15.53% increase in the stock price over the next year. The lowest target is $20 and the highest is $42.
Price Target: $30.8 (+15.53%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for KalVista Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 3 | 3 | 4 | 2 | 2 |
| Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 5 | 5 | 6 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $37 → $27 | Strong Buy → Hold | Downgrades | $37 → $27 | +1.28% | May 1, 2026 |
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 30, 2026 |
| Stifel | Stifel | Strong Buy Maintains $39 → $42 | Strong Buy | Maintains | $39 → $42 | +57.54% | Mar 26, 2026 |
| Citizens | Citizens | Buy Maintains $29 → $28 | Buy | Maintains | $29 → $28 | +5.03% | Mar 26, 2026 |
| Needham | Needham | Strong Buy Maintains $35 → $36 | Strong Buy | Maintains | $35 → $36 | +35.03% | Mar 25, 2026 |
Financial Forecast
Revenue This Year
208.97M
from 73.62M
Increased by 183.86%
Revenue Next Year
329.72M
from 208.97M
Increased by 57.78%
EPS This Year
-1.29
from -3.05
EPS Next Year
0.73
from -1.29
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 261.8M | 458.0M | ||||||
| Avg | 209.0M | 329.7M | ||||||
| Low | 178.7M | 228.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 255.6% | 119.2% | ||||||
| Avg | 183.9% | 57.8% | ||||||
| Low | 142.7% | 9.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.10 | 1.11 | ||||||
| Avg | -1.29 | 0.73 | ||||||
| Low | -1.67 | 0.28 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.